Cambodia

Located in the Greater Mekong Subregion (GMS), Cambodia was a signatory of the APLMA roadmap in 2015.

‍

While cases in Cambodia have steadily declined, malaria is increasingly focalized in hard-to-reach areas, especially in forest-fringe and deep-forest areas in the Northeastern and Southwestern regions. Since late 2020, the country has been implementing the Last Mile Project, a package of interventions, including targeted drug administration (TDA) for the highest risk group, intermittent preventive therapy for forest-goers (IPTf), and weekly active fever screening (AFS) to accelerate elimination of P. falciparum. This has been further expanded to P. vivax indigenous cases since 2024.  

‍

Having completed an initial Sustainability & Transition Readiness Assessment in 2021, Cambodia is increasing its efforts towards sustainability planning by conducting an updated assessment in 2024.  Taken together, the assessments informed the development of a Sustainability & Transition Roadmap for Malaria which aims to ensure sustained malaria elimination efforts amidst donor transition.

‍

Cambodia is part of the Regional Artemisinin-resistance Initiative (RAI), a special multi-country award from the Global Fund which aims to accelerate malaria elimination in the GMS, including drug-resistant P. falciparum malaria. Like other countries in the GMS, Cambodia also faces the challenges of an increasing proportion of P. vivax malaria.

‍

Currently among the countries making up 1% of the Asia Pacific’s malaria burden, Cambodia aims to eliminate all species of human malaria by 2025.